Finance

Lists
EMCURE:NSE
Emcure Pharmaceuticals Ltd
2 348,00 INR
+1,45%
(+33,60) 1D
13-ноя., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for EMCURE...
Open
2 325,00 INR
High
2 395,00 INR
Low
2 315,40 INR
Mkt. cap
447,37 млд
Avg. vol.
229,26 миң
Volume
294,54 миң
Dividend
0,15%
Quarterly dividend
0,90 INR
Ex-dividend date
2026-ж., 4-сен.
P/E ratio
49,29
52-wk high
2 429,90 INR
52-wk low
1 312,30 INR
EPS
47,64 INR
No. of employees
7 миң
Open
2 325,00 INR
High
2 395,00 INR
Low
2 315,40 INR
Mkt. cap
447,37 млд
Avg. vol.
229,26 миң
Volume
294,54 миң
Dividend
0,15%
Quarterly dividend
0,90 INR
Ex-dividend date
2026-ж., 4-сен.
P/E ratio
49,29
52-wk high
2 429,90 INR
52-wk low
1 312,30 INR
EPS
47,64 INR
No. of employees
7 миң
News stories
From web sources and news partners
Profile
Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company, headquartered in Pune. Emcure's product portfolio includes tablets, capsules and injectables. The company produces gynaecology, cardiovascular, oncology and blood therapeutic drugs, HIV antivirals and other anti-infectives, and vitamins and minerals. Wikipedia
About Emcure Pharmaceuticals Ltd
CEOSatish Ramanlal Mehta
Employees6,91 миң
Founded1981-ж., 16-апр.
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteemcure.com
Last report
2026-ж., 3-ноя.
Fiscal period
Q2 2027
17,14 INR / 14,90 INR
+15,03%beat
Revenue / Est. (INR)
28,20 млд / 26,52 млд
+6,35%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
23,63 млд
24,70 млд
25,80 млд
28,20 млд
Cost of goods sold
9,62 млд
10,93 млд
10,73 млд
11,42 млд
Cost of revenue
9,62 млд
10,93 млд
10,73 млд
11,42 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,87 млд
7,21 млд
4,09 млд
4,35 млд
Operating expense
10,46 млд
9,97 млд
11,09 млд
12,13 млд
Total operating expenses
20,08 млд
20,90 млд
21,82 млд
23,55 млд
Operating income
3,55 млд
3,79 млд
3,98 млд
4,65 млд
Other non operating income
18,53 млн
-363,67 млн
20,71 млн
32,54 млн
EBT including unusual items
3,14 млд
3,41 млд
3,94 млд
4,46 млд
EBT excluding unusual items
3,52 млд
3,72 млд
3,92 млд
4,46 млд
Income tax expense
824,22 млн
974,40 млн
1,01 млд
1,21 млд
Effective tax rate
26,27%
28,56%
25,67%
27,09%
Other operating expenses
5,54 млд
1,70 млд
5,90 млд
6,69 млд
Net income
2,31 млд
2,43 млд
2,94 млд
3,26 млд
Net profit margin
9,75%
9,86%
11,39%
11,54%
Earnings per share
13,67
14,70
15,34
17,14
Interest and investment income
-
16,83 млн
-
-
Interest expense
-379,75 млн
-92,49 млн
-315,36 млн
-355,76 млн
Net interest expenses
-379,75 млн
-75,66 млн
-315,36 млн
-355,76 млн
Depreciation and amortization charges
1,05 млд
1,06 млд
1,10 млд
1,10 млд
EBITDA
4,37 млд
4,67 млд
5,02 млд
5,75 млд
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору